Pharmaceutical The European Medicines Agency says it has been formally notified by the Irish subsidiary of US drugmaker Alkermes (Nasdaq: ALKS) of its decision to withdraw its application for a centralized marketing authorization for the medicine Megestrol Alkermes (megestrol), 125mg/ml oral suspension. Megestrol Alkermes was intended to be used for the treatment of anorexia, cachexia or an unexplained significant weight loss in adult AIDS and oncology patients. 13 March 2012